Research programme: cannabinoid receptor CB1 antagonists - Prosidion

Drug Profile

Research programme: cannabinoid receptor CB1 antagonists - Prosidion

Latest Information Update: 31 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Prosidion
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 18 Jan 2006 (OSI) Prosidion is the diabetes and obesity business unit of OSI Pharmaceuticals
  • 01 Jun 2005 Preclinical trials in Obesity in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top